Studies over the last decade have dramatically changed our understanding of the early natural history of rheumatoid arthritis (RA) by demonstrating convincingly that RA-related autoantibodies are elevated in asymptomatic individuals for at least several years prior to the development of clinically apparent signs and symptoms of RA. This autoantibody positive but asymptomatic phase is then followed shortly before the onset of clinically apparent signs and symptoms of arthritis by the development of increased systemic inflammation that is manifest by elevated serum/plasma levels of cytokines and chemokines. Because of these findings, we now have a general conceptual framework of how the disease develops in its earliest phases. However, despite these gains in knowledge, the initial citrullinated epitopes to which pathogenic B and T cells respond are unknown. This knowledge is critical to our understanding of the immunologic mechanisms that underlie disease development as well as the future design of tolerance-based therapies. We have established a unique cohort of individuals under the umbrella of the Studies of the Etiology of Rheumatoid Arthritis (SERA) who are at the highest definable risk for the future development of RA. Two Co-Investigators in this project application, Drs. Robinson and Buckner, have developed novel approaches to identify and characterize antigen-specific B and T cell responses to citrullinated and other RA-related autoantigens. To advance our understanding of the autoimmune response at the earliest time points in the development of RA, we propose to utilize these techniques in high-risk SERA participants and pursue the following Specific Aims:
Specific Aim #1. Identify the innate and adaptive immune response modifications that are causally associated with the break in tolerance to citrullinated autoantigens and progression to active disease;
Specific Aim #2. Use novel single-B-cell expression techniques to identify the RA-related autoantigens that are targeted in the initial preclinical phases of disease development;
and Specific Aim #3. Determine what peptide autoantigens are recognized by T cells in the initial phases of the loss of self tolerance in the preclinical period of disease development.

Public Health Relevance

The proposed research is relevant to public health because it utilizes a unique cohort of subjects and biomaterials and is focused on a strategy that will improve our understanding of the mechanisms whereby individuals develop preclinical autoimmunity and then subsequently transition to clinically apparent rheumatoid arthritis (RA). Unique antigens and epitopes recognized by subjects who are progressing to the development of RA will be defined. The proposed research will address questions directly bearing on the programmatic goals of NIAID that are focused on supporting research into the causes, treatment and prevention of autoimmune diseases.

Agency
National Institute of Health (NIH)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01AI101981-03
Application #
8691721
Study Section
Special Emphasis Panel (ZAI1)
Program Officer
Esch, Thomas R
Project Start
Project End
Budget Start
Budget End
Support Year
3
Fiscal Year
2014
Total Cost
Indirect Cost
Name
University of Colorado Denver
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
City
Aurora
State
CO
Country
United States
Zip Code
80045
Holers, V Michael (2014) Insights from populations at risk for the future development of classified rheumatoid arthritis. Rheum Dis Clin North Am 40:605-20
James, Eddie A; Rieck, Mary; Pieper, Jennifer et al. (2014) Citrulline-specific Th1 cells are increased in rheumatoid arthritis and their frequency is influenced by disease duration and therapy. Arthritis Rheumatol 66:1712-22
Sokolove, Jeremy; Johnson, Dannette S; Lahey, Lauren J et al. (2014) Rheumatoid factor as a potentiator of anti-citrullinated protein antibody-mediated inflammation in rheumatoid arthritis. Arthritis Rheumatol 66:813-21
Demoruelle, M Kristen; Deane, Kevin D; Holers, V Michael (2014) When and where does inflammation begin in rheumatoid arthritis? Curr Opin Rheumatol 26:64-71
Pieper, J; Johansson, S; Snir, O et al. (2014) Peripheral and site-specific CD4(+) CD28(null) T cells from rheumatoid arthritis patients show distinct characteristics. Scand J Immunol 79:149-55
Tan, Yann-Chong; Kongpachith, Sarah; Blum, Lisa K et al. (2014) Barcode-enabled sequencing of plasmablast antibody repertoires in rheumatoid arthritis. Arthritis Rheumatol 66:2706-15
Robinson, William H; Lindstrom, Tamsin M; Cheung, Regina K et al. (2013) Mechanistic biomarkers for clinical decision making in rheumatic diseases. Nat Rev Rheumatol 9:267-76
Willis, Van C; Demoruelle, M Kristen; Derber, Lezlie A et al. (2013) Sputum autoantibodies in patients with established rheumatoid arthritis and subjects at risk of future clinically apparent disease. Arthritis Rheum 65:2545-54